A minimal impact of long-term S-flurbiprofen plaster application on kidney function in osteoarthritis patients

Noboru Otsuka, Ikuko Yataba, Isao Matsushita, Hideo Matsumoto, Yuichi Hoshino, Yoshio Terada

研究成果: Article

3 引用 (Scopus)

抄録

Background: The number of kidney injury due to nonsteroidal anti-inflammatory drugs (NSAIDs) is the largest among drug-induced kidney diseases. Newly developed NSAID plaster containing S-flurbiprofen (SFP) shows innovative percutaneous absorption. However, systemic exposure to SFP following the repeated application of 80 mg/day was estimated as comparable to that of oral 120 mg/day flurbiprofen and prolonged use of topical NSAIDs is common in clinical practice. Thus, we report the safety focusing on the kidney function after long-term application of SFP plaster (SFPP). Methods: A total of 201 osteoarthritis patients (mean age; 66.3, 151 females, mean estimated glomerular filtration rate; 74.6 mL/min/1.73 mm2) were applied 40 or 80 mg SFPP for 52 weeks, and kidney function was examined by blood urea nitrogen (BUN), serum creatinine (SCr), eGFR, and urinalysis. Results: 161 (80.1%) patients completed 52-week application. In both groups of 40 and 80 mg, small but statistically significant increases were observed in BUN (mean 1.91 and 1.89 mg/dL, p < 0.05) and SCr (mean 0.019 and 0.022 mg/dL, p < 0.05). Although abnormal changes in laboratory test for renal function were observed in seven patients, all the changes were small and subclinical. Acute kidney injury was observed in two patients. Meanwhile, the investigators denied the relevance of SFPP according to the clinical course. Conclusion: Toward the end of 52-week application, a statistically significant increase in SCr was observed in both 40 and 80 mg, but increment was small and subclinical. Attention should be paid to kidney function when applying SFPP to patients with multiple risk factors.

元の言語English
ページ(範囲)1-8
ページ数8
ジャーナルClinical and Experimental Nephrology
DOI
出版物ステータスAccepted/In press - 2017 4 4

Fingerprint

Flurbiprofen
Osteoarthritis
Kidney
Creatinine
Anti-Inflammatory Agents
Blood Urea Nitrogen
Pharmaceutical Preparations
Serum
Skin Absorption
Urinalysis
Kidney Diseases
Glomerular Filtration Rate
Acute Kidney Injury
Research Personnel
Safety
Wounds and Injuries
spleen fibrinolytic proteinase (human)

ASJC Scopus subject areas

  • Physiology
  • Nephrology
  • Physiology (medical)

これを引用

A minimal impact of long-term S-flurbiprofen plaster application on kidney function in osteoarthritis patients. / Otsuka, Noboru; Yataba, Ikuko; Matsushita, Isao; Matsumoto, Hideo; Hoshino, Yuichi; Terada, Yoshio.

:: Clinical and Experimental Nephrology, 04.04.2017, p. 1-8.

研究成果: Article

Otsuka, Noboru ; Yataba, Ikuko ; Matsushita, Isao ; Matsumoto, Hideo ; Hoshino, Yuichi ; Terada, Yoshio. / A minimal impact of long-term S-flurbiprofen plaster application on kidney function in osteoarthritis patients. :: Clinical and Experimental Nephrology. 2017 ; pp. 1-8.
@article{ce7f5eb4e28445f29462421c3288e221,
title = "A minimal impact of long-term S-flurbiprofen plaster application on kidney function in osteoarthritis patients",
abstract = "Background: The number of kidney injury due to nonsteroidal anti-inflammatory drugs (NSAIDs) is the largest among drug-induced kidney diseases. Newly developed NSAID plaster containing S-flurbiprofen (SFP) shows innovative percutaneous absorption. However, systemic exposure to SFP following the repeated application of 80 mg/day was estimated as comparable to that of oral 120 mg/day flurbiprofen and prolonged use of topical NSAIDs is common in clinical practice. Thus, we report the safety focusing on the kidney function after long-term application of SFP plaster (SFPP). Methods: A total of 201 osteoarthritis patients (mean age; 66.3, 151 females, mean estimated glomerular filtration rate; 74.6 mL/min/1.73 mm2) were applied 40 or 80 mg SFPP for 52 weeks, and kidney function was examined by blood urea nitrogen (BUN), serum creatinine (SCr), eGFR, and urinalysis. Results: 161 (80.1{\%}) patients completed 52-week application. In both groups of 40 and 80 mg, small but statistically significant increases were observed in BUN (mean 1.91 and 1.89 mg/dL, p < 0.05) and SCr (mean 0.019 and 0.022 mg/dL, p < 0.05). Although abnormal changes in laboratory test for renal function were observed in seven patients, all the changes were small and subclinical. Acute kidney injury was observed in two patients. Meanwhile, the investigators denied the relevance of SFPP according to the clinical course. Conclusion: Toward the end of 52-week application, a statistically significant increase in SCr was observed in both 40 and 80 mg, but increment was small and subclinical. Attention should be paid to kidney function when applying SFPP to patients with multiple risk factors.",
keywords = "Acute kidney injury, Drug-induced kidney disease, Kidney function, Long-term safety, Nonsteroidal anti-inflammatory drugs, S-flurbiprofen",
author = "Noboru Otsuka and Ikuko Yataba and Isao Matsushita and Hideo Matsumoto and Yuichi Hoshino and Yoshio Terada",
year = "2017",
month = "4",
day = "4",
doi = "10.1007/s10157-017-1406-9",
language = "English",
pages = "1--8",
journal = "Clinical and Experimental Nephrology",
issn = "1342-1751",
publisher = "Springer Japan",

}

TY - JOUR

T1 - A minimal impact of long-term S-flurbiprofen plaster application on kidney function in osteoarthritis patients

AU - Otsuka, Noboru

AU - Yataba, Ikuko

AU - Matsushita, Isao

AU - Matsumoto, Hideo

AU - Hoshino, Yuichi

AU - Terada, Yoshio

PY - 2017/4/4

Y1 - 2017/4/4

N2 - Background: The number of kidney injury due to nonsteroidal anti-inflammatory drugs (NSAIDs) is the largest among drug-induced kidney diseases. Newly developed NSAID plaster containing S-flurbiprofen (SFP) shows innovative percutaneous absorption. However, systemic exposure to SFP following the repeated application of 80 mg/day was estimated as comparable to that of oral 120 mg/day flurbiprofen and prolonged use of topical NSAIDs is common in clinical practice. Thus, we report the safety focusing on the kidney function after long-term application of SFP plaster (SFPP). Methods: A total of 201 osteoarthritis patients (mean age; 66.3, 151 females, mean estimated glomerular filtration rate; 74.6 mL/min/1.73 mm2) were applied 40 or 80 mg SFPP for 52 weeks, and kidney function was examined by blood urea nitrogen (BUN), serum creatinine (SCr), eGFR, and urinalysis. Results: 161 (80.1%) patients completed 52-week application. In both groups of 40 and 80 mg, small but statistically significant increases were observed in BUN (mean 1.91 and 1.89 mg/dL, p < 0.05) and SCr (mean 0.019 and 0.022 mg/dL, p < 0.05). Although abnormal changes in laboratory test for renal function were observed in seven patients, all the changes were small and subclinical. Acute kidney injury was observed in two patients. Meanwhile, the investigators denied the relevance of SFPP according to the clinical course. Conclusion: Toward the end of 52-week application, a statistically significant increase in SCr was observed in both 40 and 80 mg, but increment was small and subclinical. Attention should be paid to kidney function when applying SFPP to patients with multiple risk factors.

AB - Background: The number of kidney injury due to nonsteroidal anti-inflammatory drugs (NSAIDs) is the largest among drug-induced kidney diseases. Newly developed NSAID plaster containing S-flurbiprofen (SFP) shows innovative percutaneous absorption. However, systemic exposure to SFP following the repeated application of 80 mg/day was estimated as comparable to that of oral 120 mg/day flurbiprofen and prolonged use of topical NSAIDs is common in clinical practice. Thus, we report the safety focusing on the kidney function after long-term application of SFP plaster (SFPP). Methods: A total of 201 osteoarthritis patients (mean age; 66.3, 151 females, mean estimated glomerular filtration rate; 74.6 mL/min/1.73 mm2) were applied 40 or 80 mg SFPP for 52 weeks, and kidney function was examined by blood urea nitrogen (BUN), serum creatinine (SCr), eGFR, and urinalysis. Results: 161 (80.1%) patients completed 52-week application. In both groups of 40 and 80 mg, small but statistically significant increases were observed in BUN (mean 1.91 and 1.89 mg/dL, p < 0.05) and SCr (mean 0.019 and 0.022 mg/dL, p < 0.05). Although abnormal changes in laboratory test for renal function were observed in seven patients, all the changes were small and subclinical. Acute kidney injury was observed in two patients. Meanwhile, the investigators denied the relevance of SFPP according to the clinical course. Conclusion: Toward the end of 52-week application, a statistically significant increase in SCr was observed in both 40 and 80 mg, but increment was small and subclinical. Attention should be paid to kidney function when applying SFPP to patients with multiple risk factors.

KW - Acute kidney injury

KW - Drug-induced kidney disease

KW - Kidney function

KW - Long-term safety

KW - Nonsteroidal anti-inflammatory drugs

KW - S-flurbiprofen

UR - http://www.scopus.com/inward/record.url?scp=85017189426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017189426&partnerID=8YFLogxK

U2 - 10.1007/s10157-017-1406-9

DO - 10.1007/s10157-017-1406-9

M3 - Article

C2 - 28378068

AN - SCOPUS:85017189426

SP - 1

EP - 8

JO - Clinical and Experimental Nephrology

JF - Clinical and Experimental Nephrology

SN - 1342-1751

ER -